Outcomes After Retreatment With Inotuzumab Ozogamicin for Relapsed/Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia.

Abstract

Article Tools CASE REPORTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/PO.22.00353 JCO Precision Oncology no. 6 (2022) e2200353. Published online October 14, 2022. PMID: 36240471 Outcomes After Retreatment With Inotuzumab Ozogamicin for Relapsed/Refractory Philadelphia Chromosome–Negative B-Cell Acute Lymphoblastic Leukemia Juan Alban , MD1xJuan AlbanSearch for articles by this author; Adam DuVall , MD, MPH2xAdam DuVallSearch for articles by this author; Sandeep Gurbuxani , MBBS3xSandeep GurbuxaniSearch for articles by this author; Wendy Stock , MD2xWendy StockSearch for articles by this author; and Anand Ashwin Patel , MD2xAnand Ashwin PatelSearch for articles by this author Show More 1Department of Medicine, University of Chicago, Chicago, IL2Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL3Section of Hematopathology, Department of Pathology, University of Chicago, Chicago, IL https://doi.org/10.1200/PO.22.00353 First Page Full Text PDF Figures and Tables Supplements © 2022 by American Society of Clinical OncologyAUTHOR CONTRIBUTIONSConception and design: All authorsCollection and assembly of data: Juan Alban, Sandeep Gurbuxani, Anand Ashwin PatelData analysis and interpretation: All authorsManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Juan AlbanEmployment: AbbVie (I)Leadership: AbbVie (I), SpringWorks Therapeutics (I)Adam DuVallConsulting or Advisory Role: Jazz PharmaceuticalsSpeakers' Bureau: Jazz PharmaceuticalsSandeep GurbuxaniConsulting or Advisory Role: AbbViePatents, Royalties, Other Intellectual Property: Royalties from UpToDate for contributions to various topicsWendy StockHonoraria: AbbVie, PfizerConsulting or Advisory Role: Jazz Pharmaceuticals, Kite, a Gilead Company, Kura Oncology, GlaxoSmithKline, Morphosys, Pfizer, Servier, Deciphira, BEAm, Newave Pharmaceutical, AstraZeneca, Kronos Bio, Pluristem TherapeuticsPatents, Royalties, Other Intellectual Property: Royalties for a chapter in Up to DateTravel, Accommodations, Expenses: PfizerAnand Ashwin PatelResearch Funding: Bristol Myers Squibb/Celgene (Inst), Servier (Inst), Pfizer (Inst)No other potential conflicts of interest were reported.